Placebo News and Research

RSS

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alkermes plc today announced the presentation of data from its phase 3 clinical trial of aripiprazole lauroxil, an investigational drug candidate in development for schizophrenia, at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Fla.

18 Jun 2014

Calcium, vitamin D supplements may send blood levels too high for some women

Calcium and vitamin D are commonly recommended for older women, but the usual supplements may send calcium excretion and blood levels too high for some women, shows a new study published online today in Menopause, the journal of The North American Menopause Society.

18 Jun 2014

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

The last 20 years have been defined by progress and innovation in the multiple sclerosis (MS) field, with now 10 approved treatment options available for people living with relapsing MS, the most common form of the disease.

17 Jun 2014

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.

17 Jun 2014

New investigational drug can slow memory loss in older Individuals with risk for developing AD in future

A new research study at Rush University Medical Center and Northwestern Medicine is testing whether a new investigational treatment can slow the memory loss caused by Alzheimer's disease.

17 Jun 2014

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Combining two smoking cessation therapies is more effective than using just one for male and highly nicotine-dependent smokers who weren't initially helped by the nicotine patch, according to researchers at Duke Medicine.

17 Jun 2014

Childhood oestrogen may normalise thelarche in Turner syndrome

Treating girls with Turner syndrome with low-dose oestrogen from childhood results in earlier thelarche and a slower tempo of puberty, research shows.

16 Jun 2014

Research on effects of caffeine on young people after puberty

Caffeine intake by children and adolescents has been rising for decades, due in large part to the popularity of caffeinated sodas and energy drinks, which now are marketed to children as young as four.

16 Jun 2014

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.

12 Jun 2014

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Ferrer, a privately-held Spanish pharmaceutical company, today announces that the first patient has been recruited into a second phase III trial of Ozenoxacin, formulated as a topical treatment for infectious dermatological conditions in adult and paediatric patients with impetigo. The study is scheduled to complete in Q1, 2015.

12 Jun 2014

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Otsuka Pharmaceutical Development & Commercialization, Inc., announced today that patient enrollment has begun for a new Phase 3b study of tolvaptan for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common, life-threatening, inherited genetic kidney disorder.

11 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

New prescription weight-loss medication combines antidepressant with addiction medication

A new prescription weight-loss medication that combines a popular antidepressant with a medication for addiction will be reviewed by the Federal Drug Administration (FDA) for potential approval.

11 Jun 2014

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Alkermes plc today announced the initiation of FORWARD-3 and FORWARD-4, two of the three planned phase 3 core efficacy studies in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD).

10 Jun 2014

Celsion signs definitive asset purchase agreement to acquire EGEN

Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the development of nucleic acid-based therapeutics for the treatment of cancer and other difficult to treat diseases, today announced the signing of a definitive asset purchase agreement in which Celsion will acquire substantially all of the assets of EGEN, including its Phase Ib DNA-based immunotherapy product candidate EGEN-001 and its therapeutic platform technologies, TheraPlas™ for delivery of DNA and mRNA, TheraSilence™ for delivery of RNA, and RAST™ for Cell Enabled Expression and Secretion of RNA.

10 Jun 2014

Edison's EPI-743 receives FDA orphan drug designation for treatment of Leigh syndrome

Edison Pharmaceuticals today announced that the FDA has granted Orphan Drug status to vatiquinone for the treatment of Leigh syndrome.

9 Jun 2014

Probiotics effectively prevent hepatic encephalopathy in patients with cirrhosis of the liver

Probiotics are effective in preventing hepatic encephalopathy in patients with cirrhosis of the liver, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association. Hepatic encephalopathy is a deterioration of brain function that is a serious complication of liver disease.

9 Jun 2014

Placebo News and Research

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Calcium, vitamin D supplements may send blood levels too high for some women

Evolution of multiple sclerosis treatments: an interview with Mike Panzara, Head of MS & Neurology Clinical Development, Genzyme

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

New investigational drug can slow memory loss in older Individuals with risk for developing AD in future

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Childhood oestrogen may normalise thelarche in Turner syndrome

Research on effects of caffeine on young people after puberty

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Ferrer recruits first patient in second phase III trial of Ozenoxacin for treatment of impetigo

Otsuka Pharmaceutical begins tolvaptan Phase 3b study in patients with ADPKD

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

New prescription weight-loss medication combines antidepressant with addiction medication

Alkermes initiates FORWARD-3 and FORWARD-4 efficacy studies in pivotal clinical program for ALKS 5461

Celsion signs definitive asset purchase agreement to acquire EGEN

Edison's EPI-743 receives FDA orphan drug designation for treatment of Leigh syndrome

Probiotics effectively prevent hepatic encephalopathy in patients with cirrhosis of the liver

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Naloxegol holds hope for opioid-induced constipation

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News